Related Experiment Video
Updated: Jul 12, 2026

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
Published on: April 18, 2019
Ampicillin/sulbactam: current status in severe bacterial infections
Petros I Rafailidis1, Eleni N Ioannidou, Matthew E Falagas
1Alfa Institute of Biomedical Sciences (AIBS), Athens, Greece.
Abstract:
Ampicillin/sulbactam is a beta-lactam/beta-lactamase inhibitor combination with a broad spectrum of antibacterial activity against Gram-positive, Gram-negative and anaerobic bacteria. Data from comparative studies justify the use of ampicillin/sulbactam in a 2 : 1 ratio in various severe bacterial infections. In comparative clinical trials, ampicillin/sulbactam has proved to be a significant drug in the therapeutic armamentarium for lower respiratory tract infections and aspiration pneumonia, gynaecological/obstetrical infections, intra-abdominal infections, paediatric infections such as acute epiglottitis and periorbital cellulitis, diabetic foot infections, and skin and soft tissue infections. Of particular interest during this era of increasing antimicrobial resistance in various settings and populations is the effectiveness of sulbactam against a considerable proportion of infections due to Acinetobacter baumannii.
Related Concept Videos
Acute Pyelonephritis II: Diagnostic Studies and Management
Clinical Significance of Antibiotic Resistance
Inhibitors of Bacterial Protein Synthesis
Mechanism of Antibiotic Resistance in MRSA
Inhibitors of Gram-positive Cell Wall Synthesis
Combined Effects of Drugs: Synergism
Such synergistic combinations...